Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia

Alzheimer Disease and Associated Disorders

Volumn 13, Issue SUPPL. 3, 1999, Pages

  Möbius, Hans Jörg ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Memantine; Neuroprotection; NMDA receptors; Vascular dementia

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; MEMANTINE; NEUROPROTECTIVE AGENT;

BRAIN ISCHEMIA; CHRONIC DISEASE; HUMAN; MULTIINFARCT DEMENTIA; REVIEW;

BRAIN ISCHEMIA; CHRONIC DISEASE; DEMENTIA, VASCULAR; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; NEUROPROTECTIVE AGENTS;

EID: 0033202701     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199912001-00024     Document Type: Article

References (57)

1. Aharon-Peretz J, Kliot D. Behavioural aspects in Alzheimer's disease and in multiple lacunar infarct dementia. Eur J Neurol 1998;5(suppl 3):35.
2. Backhauss C, Karkoutly C, Welsch M, Krieglstein J. A mouse model of focal cerebral ischemia for screening neuroprotective drug effects. J Pharmacol Toxicol Methods 1992;27:27-32.
3. Barnes CA, Danysz W, Parsons CG. Effects of the uncompetitive NMDA receptor antagonist Memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 1996;8:565-71.
4. Block F, Schwarz M. Memantine reduces functional and morphological consequences induced by global ischemia in rats. Neurosci Lett 1996; 208:41-4.
5. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 1989;166:591-2.
6. Bresink I, Benke TA, Collett VJ, et al. Effects of Memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br J Pharmacol 1996;119:195-204.
7. Bresink I, Danysz W, Parsons CG, Mutschler E. Different binding affinities of NMDA receptor channel blockers in various brain regions - indication of NMDA receptor heterogeneity. Neuropharmacology 1995;34:533-40.
8. Breteler MMB. Epidemiological evidence of a connection between Alzheimer's disease and vascular dementia. Neurobiol Aging 1998; 19(suppl 4):627.
9. Cacabelos RXA, Alvarez L, Fernandeznovoa A, et al. Brain interleukin-1 beta in Alzheimer's disease and vascular dementia. Methods Find Exp Clin Pharmacol 1994;16:141-51.
10. Carter C, Rivy JP, Thuret F, Lloyd K, Scatton B. Ifenprodil and SL 82.0715 are antagonists at the polyamine modulatoty site of the NMDA receptor complex. Soc Neurosci Abstr 1989;15:326.
11. Chen HSV, Pellegrini JW, Aggarwal SK, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by Memantine - therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992;12:4427-36.
12. Chen HSV, Wang YF, Rayudu PV, et al. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker Memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 1998;86:1121-32.
13. Clements JD, Lester RAJ, Tong G, Jahr CE, Westbrook GL. The time course of glutamate in the synaptic cleft. Science 1992;258:1498-501.
14. Committee for Proprietary Medicinal Products [CPMP]. Note for guidance on medicinal products in the treatment of Alzheimer's disease. London: European Agency for the Evaluation of Medicinal Products Cpmp/EWP/553/95.
15. Danysz W, Parsons CG, Bresink I, Quack G. Glutamate in CNS disorders - a revived target for drug development. Drug News Perspect 1995a;8:261-77.
16. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci Biobehav Rev 1997;21: 455-68.
17. Danysz W, Zajaczkowski W, Parsons CG. Modulation of learning processes by ionotropic glutamate receptor ligands. Behav Pharmacol 1995b;6:455-74.
18. Ditzler K. Efficacy and tolerability of Memantine in patients with dementia syndrome. Arzneimittel-Forschung/Drug Res 1991;8:773-80.
19. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V. The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 1997;337:1667-74.
20. Ferrucci L, Guralnik JM, Salive ME, et al. Cognitive impairment and risk of stroke in the older population. J Am Geriatr Soc 1996;44:237-41.
21. 2+ in hippocampal slices. Neuropharmacology 1999:38:1253-9.
22. Frankiewicz T, Potier B, Bashir ZI, Collingridge GL, Parsons CG. Effects of Memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br J Pharmacol 1996;117:689-97.
23. Globus MYT, Busto R, Dietrich WD, Martinez E, Valdes I, Ginsberg MD. Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and γ-aminobutyric acid studied in intracerebral microdialysis. J Neurochem 1988;51:1455-64.
24. Görtelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome - a double-blind placebo-controlled study. Arzneimittel-Forschung/Drug Res 1992;42:904-13.
25. Görtelmeyer R, Pantev M, Parsons CG, Quack G. The treatment of dementia syndrome with Akatinol Memantine', a modulator of the glutamatergic system. In: von Wild K, ed. Spektrum der Neurorehabilitation. Germering, Germany: Zuckschwerdt, 1993:50-6.
26. Gsell W, Strein I, Riederer P. The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. J Neural Transm 1996;47(suppl):73-101.
27. Heim C, Sontag K-H. Memantine prevents progressive functional neurodegeneration in rats. J Neural Transm 1995;46:117-30.
28. Jellinger K. Neuropathological aspects of dementia resulting from abnormal blood and cerebrospinal fluid dynamics. Acta Neurol Belg 1976;76:83-102.
29. Jorm AF, Jolley D. The incidence of dementia. Neurology 1998;51:728-33.
30. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel - a human postmortem brain study. Eur J Pharmacol 1991;206:297-300.
31. Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke 1983;14:399-401.
32. Marcusson J, Rother M, Kittner B, et al. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Dement Geriatr. Cogn Disord 1997;8:320-8.
33. Misztal M, Frankiewicz T, Parsons CG, Danysz W. Learning deficits induced by chronic intraventricular infusion of quinolinic acid - protection by MK-801 and Memantine. Eur J Pharmacol 1996;296:1-8.
34. Mondadori C, Weiskrantz L, Buerki H, Petschke F, Fagg GE. NMDA receptor antagonists can enhance or impair learning performance in animals. Exp Brain Res 1989;75:449-56.
35. Moroney JT, Bagiella E, Desmond DW, et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology 1997;49:1096-1105.
36. Nowak L, Bregestovski P, Ascher P, Herbert A, Prochiantz A. Magnesium gates glutamate- activated channels in mouse central neurons. Nature 1984;307:462-5.
37. Pantev M, Ritter R, Görtelmeyer R. Clinical and behavioral evaluation in long-term care patients with mild to moderate dementia under Memantine treatment. Zeitschr Gerontol Psychiatry 1993;6:103-17.
38. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by Memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 1993;32:1337-50.
39. Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and Memantine. Eur J Neurosci 1996;8:446-54.
40. Parsons CG, Quack G, Bresink I, et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 1995;34:1239-58.
41. Pasquier F, Leys D. Why are stroke patients prone to develop dementia? J Neurol 1997;244:135-42.
42. Rosen WG, Terry RD, Fuid PA, Katzmann R, Peck A. Pathological verification of ischaemic score in differentiation of dementias. Ann Neurol 1980;7:486-8.
43. Rüther E, Glaser A. The NMDA-antagonist Memantine in severe dementia: results of a propective postmarketing surveillance study. Neurobiol Aging 1998;19(suppl 4):760.
44. Schulz JB, Matthews RT, Henshaw DR, Beal MF. Neuroprotective strategies for the treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 1996;71: 1043-8.
45. Seif El Nasr M, Peruche B, Rossberg C, Mennel HD, Krieglstein J, Share NN. Neuroprotective effect of Memantine demonstrated in vivo and in vitro. Eur J Pharmacol 1990;185:19-24.
46. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer's disease. The nun study. JAMA 1997;277:813-7.
47. Sparks DL. Neuropathologic links between Alzheimer's disease and vascular disease. Neurobiol Aging 1998;19(suppl 4):628.
48. Wenk GL, Danysz W, Mobley SL. Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res 1994; 655:7-11.
49. Wenk GL, Danysz W, Mobley SL. MK-801, Memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol Env Toxicol Pharmacol Sect 1995;293:267-70.
50. Wenk GL, Danysz W, Roice DD. The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. NeuroReport 1996;7: 1453-6.
51. Wenk GL, Hauss-Wegrzyniak B, Baker LM. Potential therapies for a novel animal model of Alzheimer's disease - chronic neuroinflamation of transgenic rats that overexpress human β-amyloid. Neurobiol Aging 1998;19(suppl 4):129.
52. Wenk GL, Zajaczkowski W, Danysz W. Neuroprotection of acetylcholinergic basal forebrain neurons by Memantine and neurokinin B. Behav Brain Res 1997;83:129-33.
53. Wimo A, Karlsson, G, Sandman PO, Corder L, Winblad B. Cost of illness due to dementia in Sweden. Int J Geriatr Psychiatry 1997;12:857-61.
54. Winblad B, Poritis N. Clinical improvement in a placebo-controlled trial with Memantine in care-dependent patients with severe dementia. Neurobiol Aging 1998;19(suppl 4):1267.
55. Winblad B, Poritis N. Memantine in severe dementia. Int J Geriatr Psychiatry 1999;14:135-46.
56. Zajaczkowski W, Frankiewicz T, Parsons CG, Danysz W. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 1997;36:961-71.
57. Zajaczkowski W, Quack G, Danysz W. Infusion of (+)-MK-801 and Memantine - contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 1996;296:239-46.